OTCPK:EMMBF - Post by User
Comment by
Invest4Life2016on Dec 21, 2016 1:52pm
107 Views
Post# 25630854
RE:RE:RE:RE:Almost half a million shares sold short.....
RE:RE:RE:RE:Almost half a million shares sold short.....@ Smarthoney: You ran some simulations on paper and just figured out that none of the MMJ plays have any significant revenue? LOL I easily found that out by reading their financial statements. Also your copy and paste of EMC's analysis was also fricking hilarious for there's no historic data on EMC since they're only a week old LOL.
Just because you made some money doesn't qualify you as some savvy investor now. About 8 years ago a buddy turned a $120grand into almost $1million - after 2 years of bragging how he was so gifted and knowledgeable he had lost 80%. Telling people what they should do based on your baseless analysis and on how you made money after the fact reveals you're just here for cheap shares and to falsely feed your ego.
Anybody with a half a brain knows MMJ stocks are extremely overvalued when going by their revenue, but these 3 huge spikes since 2014 of course are just speculation looking ahead to what could be a $7-$10 billion market in Canada once it's legalized.
The last 3 years the MMJ plays have been racing to obtain as many MMJ patients as they can for a piece of that market. The recreational market is at least 10X the size of the medical market, so that's where the true race for huge market share will begin between these plays. CGC's strategy has been to buyout other plays to become the most prominent play, but still that's no guarantee that recreational users are going to flock to them or the other big names like Aphria, or Organigram. It's going to come down to branding and their methods of market penetration. Investors are counting the eggs before they're even being laid - so the word "risky" is best used to describe all of these stocks for now. CGC has lost a 3rd of it's market cap in 2 weeks and still has lots to lose as do the majority. EMC's $27million in cash is nice as is their focus on the pharma side so I don't think this one will dip below $2 unless the sector in whole gets some negative news. Should be an interesting few months ahead!